Mithra Signs Partnership Agreement With Itrom for Commercialization of Estelle® in the Middle East

  • Mithra strengthens its presence in the Middle East with a third partnership with UAE-based ITROM Pharmaceutical Group for the combined oral contraceptive Estelle®
  • Following the publication of the positive top-line results of the Estelle® Phase III study, Mithra is intensifying its business development strategy of its potential contraceptive blockbuster in key international markets
  • Agreement follows licensing deals for Estelle® with market leaders in Europe, Russia, Canada, Brazil, Japan, South Africa and South Korea

Liege, Belgium, 28 February 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that it has signed a 20-year binding Head of Terms agreement with ITROM Pharmaceutical Group (ITROM) for the commercialization of Estelle® in the Middle East. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate, containing 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 25 February 2019 – 17:45 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 30 January 2019 for an amount of EUR 84 690 as the result of the exercise of 15 subscription rights (warrants) pursuant to the warrant plan initiated on 2 March 2015. Following this capital increase, Mithra now has 37.664.245 outstanding shares carrying voting rights (37,639,495 outsanding shares previously).

Therefore, Mithra publishes the updated following information :

  • Share capital: EUR 27,573,880.18
  • Total number of securities carrying voting rights: 37,664,245 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,664,245 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued:
    • Pursuant to the warrant plan of 2 March 2015: 635 warrants giving right to 1,047,750 shares
    • Pursuant to the warrant plan of 5 November 2018: 1,238,339 warrant giving right to 1,238,339 shares

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

  • First veterinary R&D project concluded with one of the world’s largest animal health players, CEVA
  • Development of an innovative hormonal device for the bovine fertility market
  • Expansion of Mithra CDMO polymer technology expertise attracts new development partners

Liege, Belgium, 20 February 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces today that it has signed a contract with the CEVA Animal Health group to develop a hormonal device for the veterinary market. CEVA Animal Health is one of the ten largest veterinary pharmaceutical groups in the world and develops products that meet the specific needs of the various sectors of this market, particularly bovines.

Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe

• Crucial step taken by Mithra CDMO facility in Belgium with the production of first batch of Myring™, starting the commercial manufacturing process
• Production of commercial batches for the European markets on target
• Production capacity to be tripled, thanks to investment in state-of-the-art technology

Liege, Belgium, 13 February 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces today that its development and production center has successfully produced its first commercial batch of Myring™ for the European market. This first order of the vaginal contraceptive ring will be sold in the Czech Republic, a market worth approximately EUR 1.3 million . This production follows a 10-year non-exclusive license and supply agreement with the Polish company Adamed Group (Adamed) in December 2017.


 

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East

  • Mithra strengthens its collaboration with UAE-based ITROM Pharmaceutical Group with a consolidated deal to generate at least EUR 14 million
  • Product to be manufactured at Mithra CDMO facility in Belgium
  • Agreement follows licensing deals for Myring™ with market leaders in the US, Europe, Russia, Australia and Chile

Liège, Belgium, 12 February 2019 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces an exclusive 20-years license and supply agreement with ITROM Pharmaceutical Group (ITROM) for the commercialization of its combined hormonal contraceptive vaginal ring in the Middle East.

Mithra Strengthens Management Team With Key Appointments

  • Expansion of IR and Communications functions to support the execution of Mithra’s strategy

Liège, Belgium, 4 February 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has strengthened its IR and Communications functions with the appointments of Ms. Alexandra Deschner as Investor Relations Officer and Ms. Maud Vanderthommen as Communications Manager.